Remission induction in Behçet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H. [electronic resource]
Producer: 20040123Description: 1539-44 p. digitalISSN:- 1462-0324
- Adolescent
- Adult
- Alemtuzumab
- Antibodies, Monoclonal -- adverse effects
- Antibodies, Monoclonal, Humanized
- Antibodies, Neoplasm -- adverse effects
- Antirheumatic Agents -- adverse effects
- Behcet Syndrome -- drug therapy
- CD4 Lymphocyte Count
- Disease-Free Survival
- Drug Therapy, Combination
- Female
- Follow-Up Studies
- Humans
- Immunosuppressive Agents -- administration & dosage
- Lymphocyte Depletion -- methods
- Male
- Middle Aged
- Prednisolone -- administration & dosage
- Remission Induction
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial; Journal Article
There are no comments on this title.
Log in to your account to post a comment.